Niagen Bioscience, Inc. (NAGE)
Official siteCONSUMER DEFENSIVE • BIOTECHNOLOGY • NASDAQ
Market Cap: $163.54M
Last updated: Nov 17, 2026 at 11:03 AM ET
Niagen Bioscience, Inc. (NAGE) Financials: Revenue, Profit and Cash Flow
Niagen Bioscience reported revenue of $129.42M for the fiscal year ended Dec 31, 2025, up 29.9% from the year before. That year, net income was $17.38M with a net margin of 13.4%, operating cash flow was $13.50M and free cash flow was $13.21M. The quarter ended Sep 30, 2026 had revenue of $27.19M and net income of -$1.17M.
Revenue and Margins
The operating margin was 12.6% in the fiscal year ended Dec 2025, the highest of the 9 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $21.66M, a compound annual rate of 22.0%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $129.42M | +29.9% | 64.3% | 12.6% | 13.4% |
| Dec 2024 | $99.60M | +19.2% | 61.8% | 7.8% | 8.6% |
| Dec 2023 | $83.57M | +16.0% | 60.8% | -6.7% | -5.9% |
| Dec 2022 | $72.05M | +6.8% | 59.4% | -25.9% | -23.0% |
| Dec 2021 | $67.45M | +13.8% | 61.5% | -40.1% | -40.2% |
| Dec 2020 | $59.26M | +28.0% | 59.5% | -33.5% | -33.6% |
| Dec 2019 | $46.29M | +46.7% | 55.7% | -67.6% | -69.4% |
| Dec 2018 | $31.56M | +48.8% | 50.9% | -105.1% | -105.6% |
| Dec 2017 | $21.20M | -2.1% | 49.4% | -77.2% | -53.7% |
| Dec 2016 | $21.66M | N/A | 48.0% | -13.4% | -13.5% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 103.3% from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $129.42M | $99.60M | $83.57M | $72.05M | $67.45M | $59.26M | $46.29M | $31.56M | $21.20M | $21.66M |
| Cost of revenue | $46.23M | $38.01M | $32.79M | $29.25M | $25.96M | $23.98M | $20.52M | $15.50M | $10.72M | $11.27M |
| Gross profit | $83.19M | $61.59M | $50.78M | $42.80M | $41.49M | $35.27M | $25.77M | $16.05M | $10.48M | $10.39M |
| Research and development | $6.33M | $6.02M | $4.96M | $4.83M | $3.83M | $3.42M | $4.42M | $5.48M | $4.01M | $2.52M |
| Operating income | $16.28M | $7.73M | -$5.60M | -$18.63M | -$27.07M | -$19.85M | -$31.30M | -$33.17M | -$16.38M | -$2.91M |
| Net income | $17.38M | $8.55M | -$4.94M | -$16.54M | -$27.13M | -$19.93M | -$32.15M | -$33.32M | -$11.38M | -$2.93M |
| EBITDA | $16.85M | $8.54M | -$4.57M | -$16.74M | -$25.45M | -$18.34M | -$29.78M | -$32.40M | -$15.66M | -$2.49M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $27.19M | $29.79M | $31.47M | $33.84M | $33.99M | $31.12M | $30.48M | $29.13M | $25.58M | $22.74M | $22.15M | $21.20M |
| Gross profit | $17.11M | $19.31M | $19.98M | $21.70M | $21.93M | $20.23M | $19.33M | $18.20M | $16.24M | $13.69M | $13.46M | $12.94M |
| Operating income | -$1.59M | $700.00K | $1.58M | $4.09M | $4.24M | $3.19M | $4.77M | $7.11M | $1.60M | -$256.00K | -$731.00K | -$168.00K |
| Net income | -$1.17M | $963.00K | $6.32M | $4.13M | $4.58M | $3.61M | $5.06M | $7.18M | $1.88M | -$15.00K | -$492.00K | $114.00K |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $1.00M by $63.79M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $106.41M | $68.28M | $54.96M | $54.06M | $57.84M | $38.36M | $40.25M | $42.23M | $62.72M | $19.75M |
| Current assets | $96.81M | $64.10M | $49.53M | $46.57M | $48.91M | $32.22M | $33.52M | $36.53M | $57.18M | $15.74M |
| Cash and equivalents | $64.79M | $44.66M | $27.32M | $20.44M | $28.02M | $16.70M | $18.81M | $22.62M | $45.39M | $1.64M |
| Total liabilities | $29.87M | $22.18M | $26.51M | $25.39M | $26.11M | $21.93M | $19.80M | $15.05M | $8.89M | $9.78M |
| Short-term debt | $1.00M | $994.00K | $702.00K | $696.00K | $548.00K | $620.00K | $853.00K | $173.00K | $196.00K | $255.46K |
| Shareholder equity | $76.53M | $46.09M | $28.46M | $28.67M | $31.73M | $16.42M | $20.45M | $27.18M | $53.83M | $9.97M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $108.69M | $106.59M | $114.33M | $106.41M | $98.14M | $91.53M | $81.34M | $68.28M | $56.52M | $54.03M | $54.08M | $54.96M |
| Total liabilities | $25.62M | $24.06M | $32.00M | $29.87M | $27.46M | $27.33M | $25.99M | $22.18M | $22.15M | $23.32M | $25.13M | $26.51M |
| Cash and equivalents | $69.51M | $66.74M | $66.55M | $64.79M | $64.29M | $60.47M | $55.62M | $44.51M | $32.40M | $27.89M | $27.57M | $27.17M |
| Shareholder equity | $83.07M | $82.53M | $82.33M | $76.53M | $70.68M | $64.19M | $55.34M | $46.09M | $34.37M | $30.72M | $28.95M | $28.46M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 97.9% of operating cash flow. Share repurchases came to 1.9% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $13.50M | $12.11M | $7.12M | -$15.10M | -$24.16M | -$10.60M | -$20.44M | -$20.91M | -$9.80M | -$2.94M |
| Capital expenditures | $292.00K | $163.00K | $148.00K | $334.00K | $409.00K | $124.00K | $743.00K | $1.32M | $1.17M | $1.50M |
| Free cash flow | $13.21M | $11.95M | $6.97M | -$15.43M | -$24.57M | -$10.72M | -$21.18M | -$22.23M | -$10.97M | -$4.44M |
| Share repurchases | $251.00K | $0 | N/A | N/A | N/A | N/A | $565.00K | N/A | N/A | N/A |
| Investing cash flow | -$292.00K | -$143.00K | -$143.00K | -$334.00K | -$409.00K | -$165.00K | -$249.00K | -$1.77M | $4.60M | -$1.72M |
| Financing cash flow | $6.92M | $5.37M | -$90.00K | $7.65M | $36.09M | $8.65M | $16.88M | -$90.00K | $48.95M | $754.27K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.63M | $2.77M | -$1.19M | $679.00K | $3.69M | $1.25M | $7.88M | $8.58M | $3.50M | -$264.00K | $295.00K | $649.00K |
| Capital expenditures | N/A | N/A | $61.00K | $101.00K | $24.00K | $135.00K | $32.00K | $69.00K | $41.00K | $12.00K | $41.00K | $21.00K |
| Free cash flow | N/A | N/A | -$1.25M | $578.00K | $3.67M | $1.11M | $7.85M | $8.51M | $3.45M | -$276.00K | $254.00K | $628.00K |
Frequently Asked Questions About NAGE
What is Niagen Bioscience's annual revenue?
Niagen Bioscience reported revenue of $129.42M for the fiscal year ended Dec 31, 2025.
How fast is Niagen Bioscience's revenue growing?
Revenue was up 29.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 21.6%.
Is Niagen Bioscience profitable?
Yes. Niagen Bioscience reported net income of $17.38M for the fiscal year ended Dec 31, 2025, with a net margin of 13.4%.
How much free cash flow does NAGE generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $13.50M minus capital expenditures of $292.00K produced free cash flow of $13.21M.
How much debt does Niagen Bioscience have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $1.00M and cash and equivalents of $64.79M.
NAGE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors